[Form 4] Apellis Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Apellis Pharmaceuticals’ Chief People Officer Kelley Boucher received an equity grant of 30,146 shares of common stock in the form of restricted stock units on January 28, 2026. The award vests 25% each year over four years, subject to continued service.

Following this grant, Boucher beneficially owns 127,804 shares of Apellis common stock in direct ownership. This filing reflects routine equity-based compensation rather than an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Boucher Kelley

Role Chief People Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	30,146	$0.00	--

Holdings After Transaction: Common Stock — 127,804 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Boucher Kelley

(Last) (First) (Middle)

C/O APELLIS PHARMACEUTICALS, INC.

100 FIFTH AVENUE, 3RD FLOOR

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Apellis Pharmaceuticals, Inc. [ APLS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief People Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/28/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/28/2026		A		30,146(1)	A	$0	127,804	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This represents a Restricted Stock Unit award granted on January 28, 2026 that vest 25% annually over four years from grant date subject to continued service.

	/s/ David Watson, attorney-in-fact for Kelley Boucher	01/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does Apellis Pharmaceuticals (APLS) Form 4 filed for Kelley Boucher report?

The Form 4 reports that Chief People Officer Kelley Boucher received 30,146 restricted stock units of Apellis common stock. These units were granted as equity compensation and increase her directly owned beneficial holdings to 127,804 shares following the transaction.

How many Apellis shares did Kelley Boucher acquire in this Form 4 filing?

Kelley Boucher acquired 30,146 shares of Apellis common stock in the form of restricted stock units. The transaction code is “A,” indicating an award, with a per-share price of $0 as part of her compensation package rather than a market purchase.

What is the vesting schedule for Kelley Boucher’s 30,146 Apellis RSUs?

The 30,146 restricted stock units granted to Kelley Boucher vest 25% annually over four years from the January 28, 2026 grant date. Vesting is subject to her continued service, meaning she must remain with the company for the full award to vest.

How many Apellis shares does Kelley Boucher own after the reported transaction?

After the restricted stock unit grant, Kelley Boucher beneficially owns 127,804 shares of Apellis common stock. The ownership is reported as direct, indicating the holdings are in her name rather than through an intermediary entity or indirect structure.

Is the Kelley Boucher Form 4 transaction a market sale or purchase of Apellis stock?

The transaction is not a market sale or open-market purchase. It is an award of 30,146 restricted stock units reported with transaction code “A,” at a price of $0 per share, reflecting stock-based compensation rather than trading activity in the open market.

What role does Kelley Boucher hold at Apellis Pharmaceuticals in this Form 4?

Kelley Boucher is identified as an officer of Apellis Pharmaceuticals, serving as Chief People Officer. The Form 4 notes she is not a director or 10% owner, and the reported equity grant relates to her role as a senior executive of the company.